Skip to content

US · BLRX · BIOTECHNOLOGY

BioLineRx Ltd. (BLRX) intrinsic value and stock valuation

$0.96as of 2026-11-21 · Mkt cap 11.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioLineRx Ltd. DCF and intrinsic value

InvestorsCraft values BLRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BLRX’s statements →

BioLineRx Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Hevel Modi'in, HM 7177871 biolinerx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.19M
20112025
Net income
-$-1.18M
20112025
Free cash flow
-$-8.16M
20112025
Total equity
$23.3M+1.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.19M$28.9M$4.8M$0.00$0.00
Operating income-$-10.37M-$-20.41M-$-49.69M-$-29.16M-$-24.78M
Net income-$-1.18M-$-9.22M-$-60.61M-$-24.95M-$-27.05M
EPSd-$-287.1K-$-4.61M-$-37.65M-$-19.34M-$-24.59M
Operating cash flow-$-8.14M-$-43.87M-$-22.61M-$-26.24M-$-23.57M
Capital expenditure-$-30K-$-50K-$-300K-$-320K-$-100K
Free cash flow-$-8.16M-$-43.93M-$-22.91M-$-26.56M-$-23.67M
Total assets$40.9M$38.9M$63.9M$76.4M$81.4M
Total debt$10.2M$15M$11.6M$12.3M$4.65M
Net debt$6.9M$4.6M$7.34M$1.74M-$-8.34M
Total equity$23.3M$13.5M$13.2M$50.8M$68.1M
Cash and short-term investments$20.9M$19.6M$43M$51.1M$57.1M
Income statement
20252024202320222021
Revenue$1.19M$28.9M$4.8M$0.00$0.00
Cost of revenue$760K$9.26M$3.69M$0.00$0.00
Gross profit$430K$19.7M$1.11M$0.00$0.00
Research and development expenses$7.66M$9.15M$12.5M$17.6M$19.5M
Selling, general and administrative expenses$3.14M$28.5M$31.2M$11.5M$5.27M
Other expenses$0.00$2.4M$7.05M$0.00$40K
Operating expenses$10.8M$40.1M$50.8M$29.2M$24.8M
Cost and expenses$11.6M$49.4M$54.5M$29.2M$24.8M
Interest income$1.13M$1.83M$2.01M$690K$560K
Interest expense$1.29M$9.16M$2.17M$2.16M$980K
Depreciation and amortization$530K$4.07M$1.38M$650K$700K
Ebitda-$-220K$3.92M-$-57.09M-$-22.14M-$-25.37M
Operating income-$-10.37M-$-20.41M-$-49.69M-$-29.16M-$-24.78M
Total other income/expenses, net$8.33M$11.2M-$-10.92M$4.21M-$-2.28M
Income before tax-$-2.04M-$-9.22M-$-60.61M-$-24.95M-$-27.05M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-1.18M-$-9.22M-$-60.61M-$-24.95M-$-27.05M
Weighted average shares outstanding$4.11M$2M$1.61M$1.29M$1.1M
Weighted average diluted shares outstanding$4.11M$2M$1.61M$1.29M$1.1M
Balance sheet
20252024202320222021
Cash and short-term investments$20.9M$19.6M$43M$51.1M$57.1M
Net receivables$460K$3.86M$710K$720K$140K
Inventory$2.15M$3.15M$1.95M$200K$130K
Total current assets$23.7M$27.1M$47.2M$52M$57.4M
Property, plant and equipment, net$860K$1.35M$1.89M$2.5M$2.28M
Goodwill and intangible assets$16.4M$10.5M$14.9M$21.9M$21.7M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$17.2M$11.8M$16.7M$24.4M$24M
Total assets$40.9M$38.9M$63.9M$76.4M$81.4M
Accounts payable$3.49M$5.58M$10.9M$6.97M$5.57M
Short-term debt$4.71M$5M$3.67M$1.97M$2.92M
Deferred revenue$0.00$0.00$13M$0.00$0.00
Total current liabilities$12.1M$15.4M$42.8M$10.7M$9.72M
Long-term debt$5.44M$10M$7.92M$10.4M$1.73M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.44M$10M$19.9M$14.9M$3.58M
Capital lease obligations$980K$1.6M$1.82M$2.16M$1.89M
Total liabilities$17.6M$25.5M$50.7M$25.5M$13.3M
Common stock$73.4M$38.1M$31.4M$27.1M$21.1M
Retained earnings-$-401M-$-399.83M-$-390.61M-$-329.99M-$-305.04M
Accumulated other comprehensive income (loss)$18.2M$16.1M$17M$14.8M$12.7M
Total equity$23.3M$13.5M$13.2M$50.8M$68.1M
Total investments$17.6M$9.13M$38.7M$40.5M$44.2M
Total debt$10.2M$15M$11.6M$12.3M$4.65M
Net debt$6.9M$4.6M$7.34M$1.74M-$-8.34M
Cash flow statement
20252024202320222021
Net income-$-1.18M-$-9.22M-$-60.61M-$-24.95M-$-27.05M
Depreciation and amortization$530K$4.07M$1.38M$650K$700K
Stock-based compensation$0.00$1.14M$2.32M$2.25M$1.5M
Change in working capital$1.27M-$-21.82M$15.2M$1.24M-$-540K
Accounts receivable$3.77M-$-2.12M-$-360K$0.00$0.00
Inventory$1M-$-1.19M-$-1.95M$0.00$0.00
Accounts payable-$-3.51M$0.00$4.55M$0.00$0.00
Net cash provided by operating activities-$-8.14M-$-43.87M-$-22.61M-$-26.24M-$-23.57M
Investments in property, plant and equipment-$-30K-$-50K-$-120K-$-320K-$-100K
Acquisitions, net$0.00$0.00$0.00-$0.00$40K
Net cash used for investing activities-$-8.61M$29.4M$1.44M$4.01M-$-38.22M
Common stock issued$14M$16.4M$14.1M$14.4M$50.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.95M$20.7M$15.1M$20.4M$57.8M
Net change in cash-$-7.19M$6.18M-$-6.33M-$-2.4M-$-3.84M
Cash at end of period$3.25M$10.4M$4.25M$10.6M$13M
Operating cash flow-$-8.14M-$-43.87M-$-22.61M-$-26.24M-$-23.57M
Capital expenditure-$-30K-$-50K-$-300K-$-320K-$-100K
Free cash flow-$-8.16M-$-43.93M-$-22.91M-$-26.56M-$-23.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioLineRx Ltd.

        BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.

        CEO
        Philip A. Serlin
        Employees
        22
        Beta
        0.71

        Explore

        Frequently asked questions

        What is the intrinsic value of BioLineRx Ltd. (BLRX)?

        InvestorsCraft does not currently publish an intrinsic value for BLRX. How the IC value is calculated.

        Is BLRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for BLRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.